TEC

Across TCGA pan-cancer cohorts, TEC mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TEC data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TEC mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TEC expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where TEC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	II,III,IV	0.788	1.000	.019	8	view →
LUAD	OS	Tertile	II,III,IV	0.227	0.740	.026	4	view →
GBM	DFS	Tertile	All	1.000	0.588	.030	2	view →
PDAC	OS	Median	II,III,IV	0.780	1.000	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TEC–CCRCC (OS)

Open the CCRCC breakdown →